Transverse mylites its causes clinical features and gold standard clinical features and
"transverse myelitis"[MeSH Terms] AND diagnosis
"transverse myelitis"[MeSH Terms] AND "diagnosis"[MeSH Terms]
"transverse myelitis" AND "MRI" AND "criteria"
| Domain | Features |
|---|---|
| Motor | Bilateral paraparesis/paraplegia; initially flaccid (spinal shock), then spastic with hyperreflexia, clonus, and bilateral Babinski signs |
| Sensory | Ascending paresthesias, a clear sensory level on the trunk, loss of pain/temperature and deep sensation in feet |
| Autonomic | Urinary/fecal retention and incontinence, sexual dysfunction; hypo/hypertension, tachy/bradycardia (especially with cervical or high thoracic lesions) |
| Investigation | Findings in TM |
|---|---|
| CSF analysis | Normal in 40%; in remaining 60%: mild lymphocytic pleocytosis + elevated protein; oligoclonal bands may be present in MS |
| Serum AQP4-IgG (NMO-IgG) | Positive in NMOSD; highly specific for aquaporin-4 antibody disease |
| Serum MOG-IgG | Positive in MOGAD |
| ANA, antiphospholipid antibodies | For connective tissue disease workup |
| Viral serology / PCR | HSV, VZV, CMV, EBV, enteroviruses |
| Brain MRI | MS lesions (periventricular plaques, Dawson's fingers) suggest MS etiology |
| Spine angiography | If vascular cause suspected (dural AVF, spinal cord infarction) |
| Treatment | Details |
|---|---|
| First line | IV Methylprednisolone 1000 mg/day for 3-5 days |
| Steroid-refractory | Plasma exchange (PLEX), IVIG, or cyclophosphamide |
| NMOSD | Satralizumab, eculizumab, tocilizumab (anti-IL-6/complement); azathioprine or rituximab for maintenance |
| Supportive | Bladder catheterization, DVT prophylaxis, physiotherapy, pressure care |